Skip to main content

REVIEW article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1556982

This article is part of the Research Topic Role of Gamma Delta T cells in Cancer Immuno-therapy View all articles

From Ex Vivo to In Vitro Models: Towards a Novel Approach to Investigate the Efficacy of Immunotherapies on Exhausted Vγ9Vδ2 T Cells?

Provisionally accepted
  • 1 Centre de recherche en cancérologie et immunologie intégrée Nantes (CRCI2Na), Nantes, Pays de la Loire, France
  • 2 Sanofi (France), Paris, France

The final, formatted version of the article will be published soon.

    Human γδ T cells demonstrate remarkable and diverse antitumor properties driven by TCR-dependent activation. Their non-alloreactive nature and pivotal role in cancer immunity position them as attractive targets for immunotherapies. However, upon infiltrating tumors, due to mechanisms induced by the tumor microenvironment's immune evasion strategies, these cells frequently become exhausted, greatly weakening the efficacy and antitumor potential of novel immunotherapeutic treatments. While being extensively characterized in CD8 + T cells, research on γδ T cell exhaustion remains scarce. There is a growing need for comprehensive models to investigate the reinvigoration properties of exhausted γδ T cells. This review synthesizes current strategies and models for evaluating novel immunotherapies aimed at rejuvenating exhausted γδ T cells. It explores a progression of approaches, from ex vivo studies and in vivo murine models to emerging in vitro systems. The advantages and limitations of these models are discussed to provide a comprehensive understanding of their potential in advancing therapeutic research. Furthermore, recent findings suggesting in vitro exhaustion phenotypes closely mirror those observed ex vivo highlight opportunities for preclinical innovation. By refining these models, researchers can better optimize the immunotherapies targeting this unique T cell subset.

    Keywords: t cell exhaustion, Cancer, Vγ9Vδ2 T cell, In vitro Models, Immunotherapy

    Received: 07 Jan 2025; Accepted: 31 Mar 2025.

    Copyright: © 2025 Chauvet, Bourges and Scotet. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Dorothée Bourges, Sanofi (France), Paris, France
    Emmanuel Scotet, Centre de recherche en cancérologie et immunologie intégrée Nantes (CRCI2Na), Nantes, 44 007, Pays de la Loire, France

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    95% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more